Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease

Osteoporosis International

Volumn 16, Issue 9, 2005, Pages 1141-1149

  Palomba, Stefano ^a,d   Orio Jr , Francesco ^b   Manguso, Francesco ^b   Falbo, Angela ^a   Russo, Tiziana ^a   Tolino, Achille ^b   Tauchmanovà, Libuse ^b   Colao, Annamaria ^b   Doldo, Patrizia ^a   Mastrantonio, Pasquale ^c   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d NONE   (Italy)

Author keywords

Bisphosphonates; Clinical trials; Menopause; Osteoporosis; Risedronate; Treatments

Indexed keywords

CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN; RISEDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTERITIS; EVALUATION; FEMALE; FEMUR NECK; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; NAUSEA; OSTEOPOROSIS; PATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT; SERUM; STOMACH PAIN; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FEMUR; FEMUR NECK; HUMANS; INFLAMMATORY BOWEL DISEASES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 24044458610     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1927-z     Document Type: Article

References (42)

1. Seeman E (2002) Pathogenesis of bone fragility in women and man. Lancet 359:1841-1850
2. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G (1997) Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 92:1157-1163
3. Vestergaard P (2003) Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol 15:851-856
4. Lichetenstein GR (2003) Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. Am J Gastroenterol 98:S24-30
5. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591-1597
6. Bernstein CN, Blanchard JF, Metge C, Yogendran M (2003) The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 98:1797-1801
7. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C (2002) High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 51:654-658
8. Card T, West J, Hubbard R, Logan RF (2004) Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population-based cohort study. Gut 53:251-255
9. Nishimura J, Ikuyama S (2000) Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 18:350-352
10. Compston J (2003) Glucocorticoid-induced osteoporosis. Horm Res 60 Suppl 3:77-79
11. Boling EP (2004) Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin Ther 26:1-14
12. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update. Arthritis Rheum 44:1496-1503
13. Valentine JF, Sninsky CA (1999) Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 94:878-883
14. National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
15. Altkorn D, Vokes T (2001) Treatment of postmenopausal osteoporosis. JAMA 285:1415-1418
16. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37
17. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8:2018-2026
18. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523
19. Dunn CJ, Goa KL (2004) Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. J Bone Miner Metab 22:111-119
20. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G (2004) A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 99:1122-1128
21. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology (2001) Management of Crohn's disease. Am J Gastroenterol 96:635-643
22. Palomba S, Orio F Jr, Di Carlo C, Colao A, Lombardi G, Zullo F, Mastrantonio P (2002) Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:1502-1508
23. Kiel D (1995) Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518-523
24. Rand TH, Seidl G, Kainberger F, Resch A, Hittmair K, Schneider B, Gluer CC, Imhof H (1997) Impact of spinal degenerative changes on the evaluation of bone mineral density with dual energy X-ray absorptiometry (DXA). Calcif Tissue Int 60:430-433
25. Orwell ES, Oviatt KS, Mann T (1990) The impact of osteophytic and vascular calcification on vertebral mineral density measurement in men. J Clin Endocrinol Metab 70:1202-1207
26. Masud T, Keen R, Nandra D, Jawed S, Doyle DV, Spector TD (1996) Facet joint osteoarthritis and bone density measurements. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD (eds) Osteoporosis. Elsevier Science, Amsterdam, pp 167-170
27. Egger M, Juni P, Bartlett C, CONSORT Group (Consolidated Standards of Reporting of Trials) (2001) Value of flow diagrams in reports of randomized controlled trials. JAMA 285:1996-1999
28. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 7:129-135
29. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120-126
30. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423-432
31. Dougherty JA (2002) Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. Ann Pharmacother 36:512-516
32. Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF (2002) Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 16:1895-1902
33. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229
34. Clements D, Compston JE, Evans WD, Rhodes J (1993) Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 34:1543-1546
35. Haderslev KV, Tjellesen L, Sorensen HA, Staun M (2000) Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119:639-646
36. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP (2003) A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 18:1121-1127
37. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M (2003) Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17:807-816
38. von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, Bohm BO, Reinshagen M (2000) Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 12:19-24
39. Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S, Groupe D'études Thérapeutiques des Affections Inflammatoires Digestives (GETAID) (2002) Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 16:919-927
40. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, Felsenberg D, Ljunghall S, Nygard G, Persson T, Graffner H, Bianchi Porro G, Ferguson A (2002) Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 16:1519-1527
41. Navarro F, Hanauer SB (2003) Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol 98 [Suppl 12]:S18-23
42. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262